Editas Medicine (EDIT) Misses Q4 EPS by 22c

Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.55), $0.22 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $30.6 million versus the consensus estimate of $29.59 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Guggenheim Upgrades Editas Medicine (EDIT) to Buy
• Cintas beats estimates but stock edges lower
• Stitch Fix (SFIX) call put ratio 4.9 calls to 1 put with a focus on October 2.5 and 5 calls into quarter results